RT Journal Article
SR Electronic
T1 Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.07.22276117
DO 10.1101/2022.06.07.22276117
A1 Matan Yechezkel
A1 Merav Mofaz
A1 Tal Patalon
A1 Sivan Gazit
A1 Erez Shmueli
A1 Dan Yamin
YR 2022
UL http://medrxiv.org/content/early/2022/06/08/2022.06.07.22276117.abstract
AB COVID-19 remains a global concern due to vaccine protection waning and the emergence of immuneevasive variants. While the effectiveness of a second booster vaccine dose (i.e., fourth inoculation) is well proven, its safety has yet to be fully understood, and vaccine compliance remains low. We conducted a prospective observational study to compare the short-term effects of the first and second BNT162b2 mRNA COVID-19 vaccine booster doses. 2,019 participants received smartwatches and filled in a daily questionnaire on systemic reactions to the vaccine. We found substantial changes from baseline levels in the 72 hours post-vaccination with the second booster in both self-reported and physiological reactions measured by the smartwatches. However, no significant difference in reactions was observed between the first and second boosters. We also found that participants who experienced more severe reactions to the first booster tended to likewise experience more severe reactions to the second booster. Our work supports the safety of the second booster from both subjective (self-reported questionnaires) and objective (physiological measurements) perspectives.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the European Research Council (ERC) project #949850 and the Israel Science Foundation (ISF), grant No. 3409/19, within the Israel Precision Medicine Partnership program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Before participating in the study, all the subjects were advised, both orally and in writing, as to the nature of the study and gave written informed consent. The study was approved by Maccabi Health Service's Helsinki institutional review board, protocol number 0122-20-MHS.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResearchers interested in obtaining an aggregated version of the data sufficient to reproduce the results reported in this paper should contact the corresponding author.